You are here

US FDA approves Lilly migraine drug; price same as rivals

[NEW YORK] Eli Lilly and Co on Thursday said the US Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.

Lilly said it plans to sell the drug, known chemically as galcanezumab, at a list price of US$6,900 a year, or US$575 month. That is identical to the list prices for the other new migraine treatments, Aimovig from Amgen Inc and Novartis AG , and Teva Pharmaceutical Industries Ltd's Ajovy.

The three medicines, most commonly administered as monthly self-injections, belong to a class of biotech drugs known as CGRP inhibitors that block a protein involved in setting off migraines. CGRP, or calcitonin gene-related peptide, is believed to be involved in the migraine process, such as dilation of blood vessels in the brain.


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to